Search
Nashville, TN Paid Clinical Trials
A listing of 1255 clinical trials in Nashville, TN actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
997 - 1008 of 1255
There are currently 1255 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Depression Clinical Trial
Recruiting
Join us in researching a potential investigational treatment for Depression. Reimbursement for study-related expenses may be available to you.
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Qualifying participants:
•Are between 18-65
•Have been experiencing a major depressive episode for at least a month
Conditions:
Depression
Major Depressive Disorder
Depressive Disorder
Depressive Symptoms
Depressive Disorder
Featured Trial
Stroke Clinical Study
Recruiting
A clinical study for people that suffer with Stroke
Conditions:
Stroke
Canakinumab for the Prevention of Progression to Cancer in Patients with Clonal Cytopenias of Unknown Significance, IMPACT Study
Recruiting
This phase II trial tests how well canakinumab works to prevent progression to cancer in patients with clonal cytopenias of unknown significance (CCUS). CCUS is a blood condition defined by a decrease in blood cells. Blood cells are composed of either red blood cells, white blood cells, or platelets. In patients with CCUS, blood counts have been low for a long period of time. Patients with CCUS also have a mutation in one of the genes that are responsible for helping blood cells develop. The com... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/20/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Clonal Cytopenia of Undetermined Significance
Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Recruiting
The aim of this study is to identify the optimal dose for Vosilasarm (EP0062) as monotherapy and in combination with standard-of-care therapies to assess its Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients with Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
Intramedullary Calcium Sulfate Antibiotic Depot
Recruiting
The goal of this randomized clinical trial is to study the best treatment for open lower leg fractures to prevent infection. The main questions it aims to answer is if treating tibia fracture patients with a calcium sulfate antibiotic depot is better at preventing infection that the standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Open tíbia Fracture, Osteomyelitis Tibia, Tibial Fractures
Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)
Recruiting
This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite the use of inhaled steroids and with excess body weight. This study will test the central hypothesis that semaglutide will improve asthma control and reduce airway inflammation due to direct effects on the respiratory tract in adult asthma associated with obesity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Asthma
Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 Mg) Intravitreal Implants Vs Observation for Prevention of VA Loss Due to Radiation Retinopathy
Recruiting
This randomized controlled trial will evaluate the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: Tennessee Retina, PC, Nashville, Tennessee
Conditions: Radiation Retinopathy, Visual Impairment
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed with Autograft in Patients Undergoing Posterolateral Lumbar Fusion
Recruiting
This is a phase IV post-marketing study for MagnetOs Easypack Putty. MagnetOs Easypack Putty is a synthetic bone graft extender product that is routinely used by surgeons as a treatment for patients with degenerative disc disease or spinal trauma undergoing spinal fusion surgery.
In this study, MagnetOs Easypack Putty will be used according to the latest U.S. Instructions For Use, standalone in the posterolateral spine.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/14/2025
Locations: Tennessee Orthopaedic Alliance, Nashville, Tennessee
Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals
Recruiting
Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by creating molecularly-driven signatures of susceptibility and resilience, provide novel insight into disease severity, and potentially identify... Read More
Gender:
ALL
Ages:
Between 15 years and 80 years
Trial Updated:
02/14/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Unaffected Mutation Carriers: Healthy Participants With a Known BMPR2 Gene Mutation and Normal Pulmonary Pressure and RV Function on Echo, Healthy Individuals With no Cardiopulmonary Disease
The Vanderbilt Atrial Fibrillation Ablation Registry
Recruiting
The Vanderbilt Atrial Fibrillation Ablation registry (VAFAR) is a prospective clinical and genetic biorepository that systematically enrolls patients undergoing atrial fibrillation (AF) ablation. The registry was started in 2011 and has greater than 1000 AF ablation records with stored blood and DNA samples. The goals of VAFAR are to: 1) identify clinical, genetic, and serological predictors of response to AF ablation in order to improve patient selection, and 2) to provide a resource for transl... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Atrial Fibrillation
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
Recruiting
This Phase 3, single-arm, multicenter study will evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with low-grade non-muscle invasive bladder cancer (LG-NMIBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Urology Associates P.C. - Nashville, Nashville, Tennessee
Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
Milieu Teaching-AV (MT-AV Pilot)
Recruiting
This project will look at whether a novel approach to language intervention that encourages looking to audiovisual speech cues for infants with autistic older siblings (Baby Sibs), who are highly likely be diagnosed with autism or developmental language disorder (DLD). This study will specifically look at (a) whether caregivers find this approach to be easy to implement in their homes, (b) whether they find this approach to be acceptable, and (c) whether caregivers use the taught strategies in i... Read More
Gender:
ALL
Ages:
Between 5 months and 12 months
Trial Updated:
02/13/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Autism Sibling, Autism Spectrum Disorder
Outcomes and Health Care Resource Utilization in Pediatric Congenital Heart Disease Patients Undergoing Non-Cardiac Procedures
Recruiting
The incidence of moderate to severe congenital heart disease (CHD) in the United States is estimated to be 6 per 1000 live-born full term infants. Recent advances in pediatric cardiology, surgery and critical care have significantly improved the survival rates of patients with CHD leading to an increase in prevalence in both children and adults. Children with CHD significant enough to require cardiac surgery frequently also undergo non-cardiac surgical procedures. Analysis of the Pediatric Healt... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
02/12/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Congenital Heart Disease in Children
A Pragmatic Randomized Controlled Trial to Predict Postpartum Hemorrhage
Recruiting
This research project aims to enhance the safety of childbirth by using advanced computer models to predict the risk of postpartum hemorrhage (PPH).
PPH is a significant concern for mothers during and after delivery. Current risk assessment tools are basic and do not adapt to changing conditions. This study will investigate whether a new and recently validated model for predicting PPH, combined with a provider-facing Best Practice Advisory (BPA) regarding currently recommended strategies trigge... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
02/12/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Post Partum Hemorrhage
997 - 1008 of 1255
